secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001178913-25-002333
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions
--------------------------------------------------------------------------------

- Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.
- Shares and warrants transfer from Global Market to Nasdaq Capital Market effective July 8, 2025, under same symbols.
- To cure potential bid price deficiency, company plans 1-for-15 reverse share split after shareholder meeting on July 14, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/0001178913-25-002333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/zk2533425.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer